Galectin Therapeutics reported $-9932000 in Net Income for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Net Income Change
Abbvie ABBV:US $ 4490M 446M
Bristol Myers Squibb BMY:US $ 1278M 1094M
Galectin Therapeutics GALT:US $ -9.93M 2.71M
Gilead Sciences GILD:US $ 19M 363M
Idera Pharmaceuticals IDRA:US $ -4.18M 0.06M
Intercept Pharmaceuticals ICPT:US $ -17.28M 19M
Merk MRK:US $ 4310M 552M
Regulus Therapeutics RGLS:US $ -6.72M 0.41M
Vital Therapies VTL:US $ -20.81M 0.38M
YTE INCY:US $ 37.99M 525.86M